Skip to content
Boca Raton City Online – Lifestyle
Author:
NEKTAR THERAPEUTICS
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
March 6, 2026
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 6, 2026
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
March 6, 2026
Nektar Therapeutics Announces Proposed Public Offering
March 5, 2026
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
March 5, 2026
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
March 5, 2026
←
Previous Page
1
2
3